President Donald Trump announced emergency authorization to treat coronavirus disease 2019 patients with convalescent plasma — a move he called “a breakthrough,” one of his top health officials called “promising” and other health experts said needs more study before it’s celebrated.
In a letter describing the emergency authorization, the chief scientist for the FDA, Denise Hinton, said: “Covid-19 convalescent plasma should not be considered a new standard of care for the treatment of patients with Covid-19. Additional data will be forthcoming from other analyses and ongoing, well-controlled clinical trials in the coming months.”
“This president is about cutting red tape,” Meadows said in an interview Sunday on “This Week” on ABC. “He had to make sure that they felt the heat. If they don’t see the light, they need to feel the heat because the American people are suffering.” Earlier this month, Mayo Clinic researchers reported a strong hint that blood plasma from Covid-19 survivors helps other infected patients recover. But it wasn’t considered proof.
Administration officials, in a call with reporters Sunday, discussed a benefit for patients who were within three days of admission to a hospital and were not on a respirator, and were given ‘high-titer’ convalescent plasma containing higher concentrations of antibodies. They were then compared to similar patients who were given lower-titer plasma. The findings suggest deaths were 35% lower in the high-titer group.
But some health experts were skeptical. Benjamin Corb, of the American Society for Biochemistry and Molecular Biology, called it “conspicuous timing.”
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: cebudailynews - 🏆 8. / 71 Read more »
Source: manilabulletin - 🏆 25. / 51 Read more »